Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

FATE $5.27 1.5700 +42.43%
ADXS $5.61 0.7500 +15.43%
ZIOP $4.80 0.5300 +12.41%
CVM $0.65 0.0657 +11.24%
ISIS $65.09 5.5400 +9.30%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $6.11 -4.7400 -43.69%
CBMG $12.55 -1.1400 -8.33%
GTXI $0.89 -0.0800 -8.25%
PARD $0.16 -0.0100 -5.88%
GLYC $8.64 -0.4200 -4.64%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Cancer Specialists Join Baptist Health South Florida

(Baptist Health South Florida) Dec 17, 2014 - Physicians from one of the largest hematology and oncology practices in the region, Advanced Medical Specialties, have joined Baptist Health Medical Group – an organization of more than 180 physicians integrated within Baptist Health – as the founding physicians of Miami Cancer Institute.
read press release 



Practice Patterns: Young Oncologists Seek Benefits of Larger Practices, Hospitalist Jobs

(Medscape Oncology) Dec 17, 2014 - To avoid the difficulties of running a business, many young oncologists are looking for positions in well-established organizations, including universities, hospitals, and large private practices.
read article (free registration required) 



PDI Announces Launch of NGS Test for Cancer Risk Assessment

(Drug Discovery & Development) Dec 17, 2014 - PDI, Inc.'s molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules.
read article 



John Hopkins University and Compugen Team on Immune Checkpoints

(Jewish Business News) Dec 18, 2014 - The collaboration will focus on immune checkpoint candidates discovered by Compugen for the potential treatment of cancer.
read article 



Bayer Appoints Cardinal Health as U.S. Based Contract Manufacturer for Xofigo® (radium Ra 223 dichloride) Injection

(Cardinal Health) Dec 18, 2014 - Cardinal Health to build 64,000 square foot, state-of-the-art facility to manufacture radioactive therapeutic agent used to treat patients with bone metastases from castration-resistant prostate cancer
read corporate press release 



Juno Therapeutics Vies for Cancer Treatment Lead

(FT.com) Dec 17, 2014 - When Juno lists on Nasdaq on Friday, it will be one of the biggest events in a big year for the buoyant US biotech sector.
read article (free registration required) 



Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia

(NASDAQ) Dec 18, 2014 - Seattle Genetics, Inc. today announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia (AML).
read article 



Proteins Drive Cancer Cells to Change States

(MIT News) Dec 15, 2014 - A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.
read article 



Flying Time Could Raise Skin Cancer Risks for Pilots

(Drugs.com/HealthDay News) Dec 17, 2014, 2014 - Airline pilots get as much exposure to cancer-causing UV rays in an hourlong flight as they would during 20 minutes in a tanning bed, new research finds.
read article 



Low Risk of Malignancy for Small Complex Adnexal Masses

(Physician's Briefing/HealthDay News) Dec 17, 2014 - For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.
read article 



Laparoscopic Surgery for Bladder Cancer Leads to Good Long-Term Cancer Control

(Wiley) Dec 18, 2014 - Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to a study published in BJU International.
read corporate press release 



Targeted Next-generation Sequencing Reveals A High Number of Genomic Mutations in Advanced Malignant Plural Mesothelioma

(IASLC) Dec 17, 2014 - Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival.
read press release 



‘Financial Toxicity’ Can Lower Cancer Patients' Quality of Life

(Duke Today/DukeHealth.org) Dec 17, 2014 - The finding, published Dec. 16, 2014, in the Journal of Oncology Practice, advances ongoing research at Duke Medicine that has explored the issue of “financial toxicity” from cancer care and whether costs can affect a patient’s outlook and outcomes.
read article 



Merck Acquires OncoEthix for Up to $375 Million

(Wall Street Journal) Dec 18, 2014 - Merck & Co. acquired privately held OncoEthix for up to $375 million, its latest push into the oncology market as the pharmaceutical giant continues bolstering its research-and-development pipeline.
read article (paid subscription required) 



AstraZeneca First-in-class Ovarian Cancer Drug Wins EU Approval

(Reuters) Dec 18, 2014 - AstraZeneca's all-important cancer drug business received a fillip on Thursday as a new medicine against ovarian cancer was approved in Europe, making it the first of its kind to reach the market.
read article 



Lynparza™Approved in the European Union as First-in-class Treatment for Advanced BRCA-mutated Ovarian Cancer

(AstraZeneca) Dec 18, 2014 - AstraZeneca today announced that the European Commission (EC) has granted Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.
read corporate press release 



40 States Get An 'F' On Access To Doctor Information

(Forbes) Dec 16, 2014 - Most states fail when it comes to providing publicly available information on the quality of their physicians, according to a new report.
read article 



Justice Department Takes Rare Step of Dropping Misbranding Case

(Wall Street Journal) Dec 16, 2014 - Tennessee couple who ran cancer clinics charged with selling misbranded drugs.
read article 



Pozen Says FDA Rejects Two Forms of Its Lead Drug, Shares Fall

(Reuters) Dec 17, 2014 - Pozen Inc said two versions of its experimental heart drug were rejected for the second time by the U.S. Food and Drug Administration, which cited deficiencies in the manufacturing plant of a supplier of an active ingredient.
read article 



FDA Approves System That May Make Blood Transfusions Safer

(New York Times) Dec 16, 2014 - The system is being used in clinical trials in West Africa to make plasma donated by Ebola survivors safer to use as a possible treatment.
read article 



Expert in Immune Responses in Stem Cell Transplantation Joins UPCI

(UPMC) Dec 17, 2014 – Warren Shlomchik, M.D. has been named director of stem cell transplantation and cell therapies for the University of Pittsburgh’s Division of Hematology-Oncology and University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter, and UPCI’s scientific director of hematopoietic malignancies.
read press release 



Susan G. Komen® Applauds Reauthorization of the Breast Health Education and Awareness Requires Learning Young Act (EARLY)

(Susan G. Komen) Dec 16, 2014 - Susan G. Komen today applauds the reauthorization of the Breast Health Education and Awareness Requires Learning Young Act, or EARLY Act. The Act’s passage will allow for the continuation of breast health education and awareness campaigns aimed towards young and high-risk women for five more years.
read press release 



Oncodesign Has Entered Into a Services Agreement with Eisai to Develop a New Personalized Medicine Program in Earlier Line Metastatic Breast Cancer Treatment

(Yahoo! Finance) Dec 17, 2014 - ONCODESIGN announced today the signing of an agreement with Eisai Inc.
read article 



Boston Strategics Enters into an Innovative Risk-Sharing Agreement with the MD Anderson Cancer Center to Conduct a Phase 1/2a Clinical Trial of E6201 in Patients with Advanced Hematologic Malignancies Including Acute Myeloid Leukemia

(Reuters) Dec 16, 2014 - Boston Strategics Corporation (BSC) today announced that it has entered into a risk-sharing agreement with the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a Phase 1/2a clinical trial of E6201 in patients with advanced hematologic malignancies, including acute myeloid leukemia (AML).
read article 



Few Employers Cover Egg Freezing For Women With Cancer

(NPR Shots blog/Kaiser Health News) Dec 16, 2014 - Women's health advocates say that the much-publicized changes for fertility coverage at a few high-profile companies are still relatively rare, even for women with serious illnesses like cancer who want to preserve their fertility.
read article